Alumis And ACELYRIN Announce Merger To Strengthen Immunology Pipeline

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement, combining their strengths in immunology through an all-stock transaction. Alumis, a clinical-stage biopharma company focused on precision therapies for immune-mediated diseases, will join forces with ACELYRIN, a late-stage biopharma company dedicated to accelerating transformative treatments in immunology. 

Martin Babler, President, Chief Executive Officer, and Chairman of Alumis, said in a statement, “Through this combination with ACELYRIN, Alumis will have the financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab, and build commercial capabilities. Since completing our IPO, Alumis has operated with speed and rigor, and the multiple development milestones expected in 2025 and 2026, coupled with potential additional indications for ESK-001, represent exciting breakthroughs for our patients and value-driving opportunities for the combined company’s stockholders. As we move forward together, we will maintain financial discipline and a flexible capital allocation strategy to maximise the value of our highly differentiated portfolio.”

“This merger represents the culmination of a thorough strategic review process by our Board and management team to determine the best and most value-maximizing path forward for ACELYRIN. We are confident that Alumis is the right partner to optimise the development of lonigutamab and deliver long-term stockholder value together,” commented Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the Board Transaction Committee.

As of December 31, 2024, Alumis and ACELYRIN had approximately $289 million and $448 million in cash, cash equivalents, and marketable securities, respectively. The merged company will have a strong pro forma cash position of around $737 million, providing the financial runway to advance its combined clinical pipeline. This robust funding is expected to support multiple key clinical trial data readouts and cover operational and capital expenses through 2027.

Mina Kim, Chief Executive Officer of ACELYRIN, commented, “We are pleased to join with Alumis and further advance our mission of developing and delivering transformative medicines in immunology. This merger brings together two complementary organizations and pipelines, enabling the company to leverage the benefits of combined development and commercial expertise and catalyst diversification to achieve even more together. I am deeply grateful to the entire ACELYRIN team, whose efforts have made today’s milestone possible. I am excited that Alumis shares our mission of providing patients with life-changing new treatment options.”